➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Harvard Business School
Mallinckrodt
Baxter
Express Scripts

Last Updated: November 23, 2020

DrugPatentWatch Database Preview

Litigation Details for Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC (D. Del. 2013)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC (D. Del. 2013)

Docket   Start Trial Date Filed 2013-07-24
Court District Court, D. Delaware Date Terminated 2015-12-13
Cause 35:145 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties EKR THERAPEUTICS LLC
Patents 6,660,715; 7,612,102; 7,659,291; 8,044,014; 8,048,017; 8,048,043; 8,449,909; 8,455,524; 8,557,291; 9,022,022; 9,035,031; 9,040,034
Attorneys Wendy M. Ward
Firms Barnes and Thornburg LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Cornerstone Biopharma Inc. v. Exela Pharma Sciences LLC (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2013-07-24 1 Code, involving United States Patent No. 7,612,102 (“the ’102 patent”) (attached as Exhibit A hereto… § 355(b)(1), the ’102 patent and the ’291 patent (collectively, “the Patents-in-Suit”) are listed in…. This is an action for patent infringement arising under the patent laws of the United States, …hereto), and United States Patent No. 7,659,291 (“the ’291 patent”) (attached as Exhibit B hereto). …certification”) with regard to the ’102 patent and the ’291 patent (“Exela’s Notice Letter”). External link to document
2015-07-09 105 U.S. Patent Nos. 7,612,102("the'102 patent"); 7,659,290 ("the '290 patent"… ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 7,612,102; 7,659,290; 7,659,291 and 8,455,524. Signed…CONSTRUING THE TERMS OF U.S. PATENT NOS. 7,612,102; 7,659,290; 7,659,291and8,455,5247,659,291 ("the '291 patent"); and 8,455,524 ("the '524 patent") (collectively, the… the "patents-in-suit"): 1. The term "a pre-mixed aqueous solution& External link to document
2013-08-19 20 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,612,102 B2; US 7,659,291 … 14 December 2015 1:13-cv-01275 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Moodys
Boehringer Ingelheim
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.